Literature DB >> 26201780

Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.

Chien-Hung Chen1,2, Chuan-Mo Lee1,2, Jing-Houng Wang1,2, Tsung-Hui Hu1,2, Chao-Hung Hung1,2, Chi-Sin Changchien1,2, Sheng-Nan Lu3,4.   

Abstract

PURPOSE: We investigated whether the combined presence and evolution of hepatitis B virus (HBV) mutant strains in the hepatitis B e antigen (HBeAg)-positive status can predict clinical outcomes after HBeAg seroconversion.
METHODS: One hundred and eighty-six patients with spontaneous HBeAg seroconversion were enrolled into this longitudinal study. The sequences of pre-S, core promoter, and precore regions were determined at study entry and at the visit immediately before HBeAg seroconversion.
RESULTS: Age ≥40 years at HBeAg seroconversion, male sex, and higher HBV DNA levels at entry were independent predictors for HBeAg-negative chronic hepatitis B (CHB). Patients with combined mutations of pre-S deletions and T1762/A1764 had a significantly increased risk of cirrhosis and hepatocellular carcinoma (HCC) compared to patients with the wild type at both genomic regions. Combinations of pre-S deletions and T1762/A1764 were found on the same HBV genome by cloning analysis of full-length HBV genomes. Patients with a persistent presence of pre-S deletions and T1762/A1764 mutations, and new development of pre-S deletions in the HBeAg-positive status were significantly at an increased risk of HBeAg-negative CHB, cirrhosis, and HCC after HBeAg seroconversion than those with a persistent presence of the wild type at both genomic regions. After adjusting the other risk factors, the evolution of pre-S deletions was an independent predictor for cirrhosis [hazard ratio (HR): 1.52, 95 % confidence interval (CI) 1.02-2.25] and HCC (HR: 4.0, 95 % CI 1.6-10.1).
CONCLUSIONS: The combined presence and evolution of pre-S deletions and T1762/A1764 in the HBeAg-positive status was a useful factor significantly predictive of clinical outcomes in patients with spontaneous HBeAg seroconversion.

Entities:  

Keywords:  Cirrhosis; Core promoter mutation; Hepatitis B virus; Hepatocellular carcinoma; Pre-S deletion

Year:  2012        PMID: 26201780     DOI: 10.1007/s12072-012-9381-4

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  32 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Chia-Chi Wang; Chi-Ling Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

4.  Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study.

Authors:  D Y Lin; I S Sheen; C T Chiu; S M Lin; Y C Kuo; Y F Liaw
Journal:  J Clin Ultrasound       Date:  1993-06       Impact factor: 0.910

5.  Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.

Authors:  Y F Liaw; C M Chu; I J Su; M J Huang; D Y Lin; C S Chang-Chien
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

6.  Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion.

Authors:  Shuang Wu; Fumio Imazeki; Fuat Kurbanov; Kenichi Fukai; Makoto Arai; Tatsuo Kanda; Yutaka Yonemitsu; Yasuhito Tanaka; Masashi Mizokami; Osamu Yokosuka
Journal:  J Hepatol       Date:  2010-08-25       Impact factor: 25.083

7.  Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis.

Authors:  Chao-Hung Hung; Sheng-Nan Lu; Jing-Houng Wang; Chuan-Mo Lee; Tsung-Ming Chen; Hung-Da Tung; Chien-Hung Chen; Wu-Shiung Huang; Chi-Sin Changchien
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

8.  Viral quasi-species evolution during hepatitis Be antigen seroconversion.

Authors:  Seng Gee Lim; Yan Cheng; Stephane Guindon; Bee Leng Seet; Lay Yong Lee; Peizhen Hu; Shanthi Wasser; Frank Josef Peter; Theresa Tan; Matthew Goode; Allen Gerard Rodrigo
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

9.  Precore mutations and core clustering mutations in chronic hepatitis B virus infection.

Authors:  W L Chuang; M Omata; T Ehata; O Yokosuka; Y Ito; F Imazeki; S N Lu; W Y Chang; M Ohto
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

10.  Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.

Authors:  Yi-Cheng Chen; Chia-Ming Chu; Yun-Fan Liaw
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

View more
  3 in total

1.  High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.

Authors:  Li-Fu Kuo; Chuan-Mo Lee; Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Sheng-Nan Lu; Chi-Sin Changchien; Chien-Hung Chen
Journal:  Dig Dis Sci       Date:  2014-05-21       Impact factor: 3.199

2.  Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion.

Authors:  Chien-Hung Chen; Sheng-Nan Lu; Chuan-Mo Lee; Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu
Journal:  Hepatol Int       Date:  2014-05-31       Impact factor: 6.047

Review 3.  Recent Advances in HBV Reactivation Research.

Authors:  Lixia Guo; Dan Wang; Xiping Ouyang; Ni Tang; Xuemei Chen; Yuhong Zhang; Hongquan Zhu; Xiaosong Li
Journal:  Biomed Res Int       Date:  2018-12-26       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.